Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia

Journal of Nephrology

Volumn 22, Issue 5, 2009, Pages 675-681

  Ott, Christian ^a   Ritt, Martin ^a   Titze, Stephanie I ^a   Schäufele, Tim ^b   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Heart Institute   (Germany)

Author keywords

Hypercholesterolemia; Intrarenal hemodynamics; Rosuvastatin

Indexed keywords

4 AMINOHIPPURIC ACID; INULIN; PLACEBO; ROSUVASTATIN;

ADULT; ARTERIOLE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; HYDROSTATIC PRESSURE; HYPERCHOLESTEROLEMIA; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; LIPID ANALYSIS; MALE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KIDNEY; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINES; REGIONAL BLOOD FLOW; SULFONAMIDES; VASCULAR RESISTANCE;

EID: 70649089013     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
2. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084-2091.
3. Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol. 2000;11:80-87.
4. Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003;18:265-272.
5. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int. 2000;58:293-301.
6. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131-1139.
7. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102:52-60.
8. Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol. 2006;97:1602-1606.
9. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
10. Undas A, Celinska-Lowenhoff M, Kaczor M, Musial J. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost. 2004;91:1065-1077.
11. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;23:729-736.
12. Yoshida M, Sawada T, Ishii H, et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol. 2001;21:1165-1171.
13. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282:2035-2042.
14. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int. 1981;19:410-415.
15. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
16. John S, Delles C, Jacobi J, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol. 2001;37:1351-1358.
17. Ott C, Schlaich MP, Schmidt BM, Titze SI, Schaufele T, Schmieder RE. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis. 2008;196:704-711.
18. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005;149:473.
19. Cole BR, Giangiacomo J, Ingelfinger JR, Robson AM. Measurement of renal function without urine collection: a critical evaluation of the constant-infusion technic for determination of inulin and para-aminohippurate. N Engl J Med. 1972;287:1109-1114.
20. Delles C, Jacobi J, Schlaich MP, John S, Schmieder RE. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens. 2002;15:3-9.
21. Delles C, Klingbeil AU, Schneider MP, Handrock R, Schaufele T, Schmieder RE. The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial Transplant. 2004;19:1392-1397.
22. Gomez DM. Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Invest. 1951;30:1143-1155.
23. Guidi E, Cozzi MG, Minetti EE, Civati G, Busnach G, Brando B. Effect of familial hypertension on glomerular hemodynamics and tubulo-glomerular feedback after uninephrectomy. Am J Hypertens. 2001;14:121-128.
24. Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens. 2003;16:1030-1035.
25. Schlaich MP, Schmitt D, Ott C, Schmidt BM, Schmieder RE. Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. J Hypertens. 2008;26:110-116.
26. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145:117-124.
27. Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA. Partial remission of nephrotic syndrome in patient on longterm simvastatin. Lancet. 1990;335:1045-1046.
28. Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest. 2000;30:980-987.
29. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
30. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-1295.
31. Agarwal R. Effects of statins on renal function. Am J Cardiol. 2006;97:748-755.
32. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
33. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-678.
34. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30-48.
35. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57:1803-1817.
36. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res. 1996;19:31-36.
37. Ito S, Arima S, Ren yL, Juncos LA, Carretero OA. Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest. 1993;91:2012-2019.
38. Ozawa y, Hayashi K, Nagahama T, Fujiwara K, Wakino S, Saruta T. Renal afferent and efferent arteriolar dilation by nilvadipine: studies in the isolated perfused hydronephrotic kidney. J Cardiovasc Pharmacol. 1999;33:243-247.
39. Plum J, Bunten B, Nemeth R, Grabensee B. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol. 1998;9:2223-2234.
40. Inigo P, Campistol JM, Lario S, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol. 2001;12:822-827.